GSK at a glance

Male scientist and female dressed smartly smiling in a studio

Download

GSK at a glance (PDF, 1.0MB)

A focused biopharma company

70k
People worldwide
>75
Countries we operate in
37
Manufacturing sites

Innovation

6.2bn
R&D investment in 2023 (£)
3
Strategic global R&D hubs in US, UK and Belgium
6
Major business development deals in 2023

Performance

Investors

2.3bn
Packs of medicines and doses of vaccines delivered
30.3bn
Vaccine and medicine sales in 2023 (£)
14%
Sales growth in 2023
10bn
Sales of products launched in the last five years including lifecycle innovation (£)

Scientist in a lab wearing white lab coat and goggles

Trust

Responsibility

1st
In the Access to Medicine Index
1st
In our industry for the S&P Global Corporate Sustainability Assessment
10%
Reduction in Operational Carbon emissions
12
Global Health pipeline assets progressed to address priority WHO Diseases

Products and pipeline

Pipeline

71
Assets in the pipeline
8
Phase I programmes started in 2023
18
Assets in phase III/registration in 2023
4
Major vaccines and medicines approved in 2023

23/32
Vaccine preventable diseases identified by WHO
1.5m
Vaccine doses delivered each day
4 in 10
Children receiving a GSK vaccine each year
19
Candidate vaccines in our pipeline

1st
To pioneer HIV treatments in 1980 and leaders in HIV innovation
1st
To produce a new medicine for Lupus in 50+ years
11
Investigational medicines in our oncology pipeline

700m
Patients reached with our general medicines over the next ten years
150+
Medicines in our portfolio
50 years
Of helping millions of people with respiratory conditions to breathe more easily
10.2bn
Sales growth in 2023 (£)

Key achievements

Malaria vaccine

Our ground-breaking malaria vaccine is the first and only vaccine shown in long-term clinical trials to reduce malaria in children.

Infectious diseases

Major approvals

We delivered four major product approvals in 2023 for infectious diseases, HIV and oncology.

HIV

Monoclonal antibodies

We have developed monoclonal antibodies to help treat different diseases. Monoclonal antibodies are laboratory-made proteins that work in a similar way to antibodies in the human immune system.

Respiratory/immunology

Cancer medicines

We have 11 investigational medicines in our oncology pipeline that have the potential to make a meaningful difference for patients with cancer, and we’re growing our pipeline through targeted business development.

Oncology

GSK at a glance

A focused biopharma company

You might also like

Outstanding people

Locations

Behind the science magazine